ChartMill · Jul 21, 2026
Tuesday's session: most active stocks
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action!
JU
NASDAQ · JUNS
Jupiter Neurosciences, Inc.
Healthcare · Biotechnology
$2.98
Up+$0.40 (+15.50%)
Updated Oct 24, 2026, 10:37 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 41.02M
- P/E ratio
- -5.33
- Dividend yield
- 0.00%
- 52-week range
- $0.08 – $11.20
- Volume
- 19.82K
- Avg. volume
- 119.55K
Price performance · JUNS
JUNS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
JUNS closed at $2.98 after 21 trading sessions, up 11.61% for the selected period.
- Last close
- $2.98
- Period change
- +11.61%
- Period low
- $2.42
- Period high
- $3.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $2.58 | $3.22 | $2.58 | $2.98 | 19.82K |
| Oct 22, 2026 | $2.80 | $2.80 | $2.551 | $2.58 | 10.28K |
| Oct 21, 2026 | $2.78 | $2.80 | $2.6314 | $2.78 | 28.68K |
| Oct 20, 2026 | $2.75 | $3.24 | $2.75 | $2.80 | 11.22K |
| Oct 19, 2026 | $2.77 | $2.82 | $2.75 | $2.75 | 8.49K |
| Oct 16, 2026 | $3.09 | $3.1152 | $2.8806 | $2.905 | 13.92K |
| Oct 15, 2026 | $3.16 | $3.27 | $3.025 | $3.14 | 19.81K |
| Oct 14, 2026 | $3.30 | $3.43 | $3.07 | $3.19 | 20.93K |
| Oct 13, 2026 | $3.00 | $3.4999 | $3.00 | $3.36 | 71.54K |
| Oct 12, 2026 | $2.89 | $3.04 | $2.7604 | $3.04 | 37.24K |
| Oct 9, 2026 | $2.83 | $2.89 | $2.67 | $2.85 | 7.04K |
| Oct 8, 2026 | $2.70 | $2.8499 | $2.6604 | $2.77 | 36.89K |
| Oct 7, 2026 | $2.61 | $2.8579 | $2.5801 | $2.84 | 47.08K |
| Oct 6, 2026 | $2.38 | $3.18 | $2.251 | $2.86 | 927.42K |
| Oct 5, 2026 | $2.425 | $2.55 | $2.3301 | $2.42 | 14.94K |
| Oct 2, 2026 | $2.50 | $2.60 | $2.50 | $2.55 | 11.99K |
| Oct 1, 2026 | $2.57 | $2.57 | $2.39 | $2.50 | 13.38K |
| Sep 30, 2026 | $2.51 | $2.61 | $2.35 | $2.44 | 16.8K |
| Sep 29, 2026 | $2.54 | $2.60 | $2.38 | $2.58 | 15.57K |
| Sep 28, 2026 | $2.67 | $2.67 | $2.40 | $2.51 | 53.05K |
| Sep 25, 2026 | $2.82 | $2.9659 | $2.67 | $2.67 | 59.52K |
Latest JUNS news
The latest Smart Investors Daily articles mentioning JUNS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
JUNS research
Overview
Company profile and research snapshot.
Company profile
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jul 21, 2026
Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone Payments
Agreement expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through diversification across two-clinical-stage CNS assets;
Benzinga · Feb 23, 2026
Jupiter Neurosciences Enters Into Omnibus Amendment With YA II PN, Modifying Installment Payment Provisions Of Convertible Promissory Notes Issued Under Standby Equity Purchase Agreement
Repayment Commencement Deferred to April 1, 2026Core Economic Terms of $6.0 Million Financing Remain UnchangedJUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage
Benzinga · Jan 28, 2026
Jupiter Neurosciences shares are trading lower. The company announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia consumer longevity product line.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
